TrialJournal of hematology & oncology2016

Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy.

Yongxian Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.